Stroke:华法林 vs. 4种直接口服抗凝剂,房颤患者抗凝控制好,痴呆风险小

2021-09-25 “心关注”公众号 “心关注”公众号

房颤是痴呆的一个危险因素,口服抗凝药物与降低房颤患者的痴呆风险有关。近日发表在Stroke上的一项研究比较了直接口服抗凝药物(DOACs)与华法林治疗的房颤患者痴呆发生风险。结果显示,在痴呆结局方面,

房颤是痴呆的一个危险因素,口服抗凝药物与降低房颤患者的痴呆风险有关。近日发表在Stroke上的一项研究比较了直接口服抗凝药物(DOACs)与华法林治疗的房颤患者痴呆发生风险。结果显示,在痴呆结局方面,65-74岁或有卒中病史的人群中,DOACs似乎比华法林更有益。对于特定的DOACs,只有艾多沙班比华法林的痴呆风险更低。

研究方法

使用2014年1月至2017年12月韩国全国索赔数据库,纳入了年龄≥40岁初次口服抗凝药物的非瓣膜性心房颤动患者。采用逆概率加权法对华法林组和DOAC组进行比较,主要终点是痴呆发生率。

研究结果

在72,846名研究患者中,25,948名接受华法林治疗,46,898名接受DOAC治疗(利伐沙班17,193名,达比加群9882名,阿哌沙班11,992名,艾多沙班7831名)。在平均1.3±1.1年的随访期间,痴呆的粗发病率为每年4.87/100人(血管性痴呆发病率为每年1.2/100人,阿尔茨海默病痴呆发病率为每年3.3/100人)。与华法林相比,DOAC显示痴呆、血管性痴呆和阿尔茨海默氏痴呆的风险相当。在亚组分析中,DOAC与华法林相比痴呆风险较低,特别是65-74岁患者(风险比0.815[95%CI 0.709-0.936])和既往卒中患者(风险比 0.891[95%CI 0.820-0.968)。当比较单个DOAC与华法林时,艾多沙班与痴呆风险较低相关(风险比 0.830[95%CI 0.740-0.931])。

研究结论

在庞大的亚洲房颤人群中,DOAC显示出与华法林具有同等的总体痴呆风险。在65-74岁或有卒中病史的人群中,DOACs似乎比华法林更有益。对于特定的DOACs,只有艾多沙班比华法林患痴呆的风险更低。

原始出处:

So-Ryoung Lee , Eue-Keun Choi, et al. Comparing Warfarin and 4 Direct Oral Anticoagulants for the Risk of Dementia in Patients With Atrial Fibrillation. Stroke, 2021.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1309782, encodeId=8e1b1309e824b, content=<a href='/topic/show?id=886438210fb' target=_blank style='color:#2F92EE;'>#口服抗凝剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38210, encryptionId=886438210fb, topicName=口服抗凝剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed25376, createdName=gdsun, createdTime=Mon Sep 27 03:59:39 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316798, encodeId=35cf1316e98ef, content=<a href='/topic/show?id=d3d0e121576' target=_blank style='color:#2F92EE;'>#痴呆风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71215, encryptionId=d3d0e121576, topicName=痴呆风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a98f453, createdName=pcw106, createdTime=Mon Sep 27 03:59:39 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441159, encodeId=24651441159eb, content=<a href='/topic/show?id=7f9ae242984' target=_blank style='color:#2F92EE;'>#直接口服抗凝剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72429, encryptionId=7f9ae242984, topicName=直接口服抗凝剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9a54798293, createdName=若水124, createdTime=Mon Sep 27 03:59:39 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614615, encodeId=4543161461572, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Mon Sep 27 03:59:39 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054908, encodeId=149f10549082d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc4d2208236, createdName=老龙一点, createdTime=Sun Sep 26 10:04:28 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054750, encodeId=2bec1054e50ca, content=机制呢?, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=adf5106748, createdName=15915591e7m, createdTime=Sat Sep 25 19:37:49 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1246292, encodeId=8c94124629276, content=老年性痴呆,未来还是希望借助神经电生理吧,也许更为有效!, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=neuro.Dr, createdTime=Sat Sep 25 15:59:39 CST 2021, time=2021-09-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1309782, encodeId=8e1b1309e824b, content=<a href='/topic/show?id=886438210fb' target=_blank style='color:#2F92EE;'>#口服抗凝剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38210, encryptionId=886438210fb, topicName=口服抗凝剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed25376, createdName=gdsun, createdTime=Mon Sep 27 03:59:39 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316798, encodeId=35cf1316e98ef, content=<a href='/topic/show?id=d3d0e121576' target=_blank style='color:#2F92EE;'>#痴呆风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71215, encryptionId=d3d0e121576, topicName=痴呆风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a98f453, createdName=pcw106, createdTime=Mon Sep 27 03:59:39 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441159, encodeId=24651441159eb, content=<a href='/topic/show?id=7f9ae242984' target=_blank style='color:#2F92EE;'>#直接口服抗凝剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72429, encryptionId=7f9ae242984, topicName=直接口服抗凝剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9a54798293, createdName=若水124, createdTime=Mon Sep 27 03:59:39 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614615, encodeId=4543161461572, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Mon Sep 27 03:59:39 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054908, encodeId=149f10549082d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc4d2208236, createdName=老龙一点, createdTime=Sun Sep 26 10:04:28 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054750, encodeId=2bec1054e50ca, content=机制呢?, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=adf5106748, createdName=15915591e7m, createdTime=Sat Sep 25 19:37:49 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1246292, encodeId=8c94124629276, content=老年性痴呆,未来还是希望借助神经电生理吧,也许更为有效!, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=neuro.Dr, createdTime=Sat Sep 25 15:59:39 CST 2021, time=2021-09-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1309782, encodeId=8e1b1309e824b, content=<a href='/topic/show?id=886438210fb' target=_blank style='color:#2F92EE;'>#口服抗凝剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38210, encryptionId=886438210fb, topicName=口服抗凝剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed25376, createdName=gdsun, createdTime=Mon Sep 27 03:59:39 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316798, encodeId=35cf1316e98ef, content=<a href='/topic/show?id=d3d0e121576' target=_blank style='color:#2F92EE;'>#痴呆风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71215, encryptionId=d3d0e121576, topicName=痴呆风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a98f453, createdName=pcw106, createdTime=Mon Sep 27 03:59:39 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441159, encodeId=24651441159eb, content=<a href='/topic/show?id=7f9ae242984' target=_blank style='color:#2F92EE;'>#直接口服抗凝剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72429, encryptionId=7f9ae242984, topicName=直接口服抗凝剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9a54798293, createdName=若水124, createdTime=Mon Sep 27 03:59:39 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614615, encodeId=4543161461572, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Mon Sep 27 03:59:39 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054908, encodeId=149f10549082d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc4d2208236, createdName=老龙一点, createdTime=Sun Sep 26 10:04:28 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054750, encodeId=2bec1054e50ca, content=机制呢?, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=adf5106748, createdName=15915591e7m, createdTime=Sat Sep 25 19:37:49 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1246292, encodeId=8c94124629276, content=老年性痴呆,未来还是希望借助神经电生理吧,也许更为有效!, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=neuro.Dr, createdTime=Sat Sep 25 15:59:39 CST 2021, time=2021-09-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1309782, encodeId=8e1b1309e824b, content=<a href='/topic/show?id=886438210fb' target=_blank style='color:#2F92EE;'>#口服抗凝剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38210, encryptionId=886438210fb, topicName=口服抗凝剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed25376, createdName=gdsun, createdTime=Mon Sep 27 03:59:39 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316798, encodeId=35cf1316e98ef, content=<a href='/topic/show?id=d3d0e121576' target=_blank style='color:#2F92EE;'>#痴呆风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71215, encryptionId=d3d0e121576, topicName=痴呆风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a98f453, createdName=pcw106, createdTime=Mon Sep 27 03:59:39 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441159, encodeId=24651441159eb, content=<a href='/topic/show?id=7f9ae242984' target=_blank style='color:#2F92EE;'>#直接口服抗凝剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72429, encryptionId=7f9ae242984, topicName=直接口服抗凝剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9a54798293, createdName=若水124, createdTime=Mon Sep 27 03:59:39 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614615, encodeId=4543161461572, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Mon Sep 27 03:59:39 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054908, encodeId=149f10549082d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc4d2208236, createdName=老龙一点, createdTime=Sun Sep 26 10:04:28 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054750, encodeId=2bec1054e50ca, content=机制呢?, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=adf5106748, createdName=15915591e7m, createdTime=Sat Sep 25 19:37:49 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1246292, encodeId=8c94124629276, content=老年性痴呆,未来还是希望借助神经电生理吧,也许更为有效!, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=neuro.Dr, createdTime=Sat Sep 25 15:59:39 CST 2021, time=2021-09-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1309782, encodeId=8e1b1309e824b, content=<a href='/topic/show?id=886438210fb' target=_blank style='color:#2F92EE;'>#口服抗凝剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38210, encryptionId=886438210fb, topicName=口服抗凝剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed25376, createdName=gdsun, createdTime=Mon Sep 27 03:59:39 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316798, encodeId=35cf1316e98ef, content=<a href='/topic/show?id=d3d0e121576' target=_blank style='color:#2F92EE;'>#痴呆风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71215, encryptionId=d3d0e121576, topicName=痴呆风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a98f453, createdName=pcw106, createdTime=Mon Sep 27 03:59:39 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441159, encodeId=24651441159eb, content=<a href='/topic/show?id=7f9ae242984' target=_blank style='color:#2F92EE;'>#直接口服抗凝剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72429, encryptionId=7f9ae242984, topicName=直接口服抗凝剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9a54798293, createdName=若水124, createdTime=Mon Sep 27 03:59:39 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614615, encodeId=4543161461572, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Mon Sep 27 03:59:39 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054908, encodeId=149f10549082d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc4d2208236, createdName=老龙一点, createdTime=Sun Sep 26 10:04:28 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054750, encodeId=2bec1054e50ca, content=机制呢?, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=adf5106748, createdName=15915591e7m, createdTime=Sat Sep 25 19:37:49 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1246292, encodeId=8c94124629276, content=老年性痴呆,未来还是希望借助神经电生理吧,也许更为有效!, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=neuro.Dr, createdTime=Sat Sep 25 15:59:39 CST 2021, time=2021-09-25, status=1, ipAttribution=)]
    2021-09-26 老龙一点

    学习了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1309782, encodeId=8e1b1309e824b, content=<a href='/topic/show?id=886438210fb' target=_blank style='color:#2F92EE;'>#口服抗凝剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38210, encryptionId=886438210fb, topicName=口服抗凝剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed25376, createdName=gdsun, createdTime=Mon Sep 27 03:59:39 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316798, encodeId=35cf1316e98ef, content=<a href='/topic/show?id=d3d0e121576' target=_blank style='color:#2F92EE;'>#痴呆风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71215, encryptionId=d3d0e121576, topicName=痴呆风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a98f453, createdName=pcw106, createdTime=Mon Sep 27 03:59:39 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441159, encodeId=24651441159eb, content=<a href='/topic/show?id=7f9ae242984' target=_blank style='color:#2F92EE;'>#直接口服抗凝剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72429, encryptionId=7f9ae242984, topicName=直接口服抗凝剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9a54798293, createdName=若水124, createdTime=Mon Sep 27 03:59:39 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614615, encodeId=4543161461572, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Mon Sep 27 03:59:39 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054908, encodeId=149f10549082d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc4d2208236, createdName=老龙一点, createdTime=Sun Sep 26 10:04:28 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054750, encodeId=2bec1054e50ca, content=机制呢?, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=adf5106748, createdName=15915591e7m, createdTime=Sat Sep 25 19:37:49 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1246292, encodeId=8c94124629276, content=老年性痴呆,未来还是希望借助神经电生理吧,也许更为有效!, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=neuro.Dr, createdTime=Sat Sep 25 15:59:39 CST 2021, time=2021-09-25, status=1, ipAttribution=)]
    2021-09-25 15915591e7m

    机制呢?

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1309782, encodeId=8e1b1309e824b, content=<a href='/topic/show?id=886438210fb' target=_blank style='color:#2F92EE;'>#口服抗凝剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38210, encryptionId=886438210fb, topicName=口服抗凝剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ed25376, createdName=gdsun, createdTime=Mon Sep 27 03:59:39 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316798, encodeId=35cf1316e98ef, content=<a href='/topic/show?id=d3d0e121576' target=_blank style='color:#2F92EE;'>#痴呆风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71215, encryptionId=d3d0e121576, topicName=痴呆风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a98f453, createdName=pcw106, createdTime=Mon Sep 27 03:59:39 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441159, encodeId=24651441159eb, content=<a href='/topic/show?id=7f9ae242984' target=_blank style='color:#2F92EE;'>#直接口服抗凝剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72429, encryptionId=7f9ae242984, topicName=直接口服抗凝剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9a54798293, createdName=若水124, createdTime=Mon Sep 27 03:59:39 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614615, encodeId=4543161461572, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Mon Sep 27 03:59:39 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054908, encodeId=149f10549082d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc4d2208236, createdName=老龙一点, createdTime=Sun Sep 26 10:04:28 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054750, encodeId=2bec1054e50ca, content=机制呢?, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=adf5106748, createdName=15915591e7m, createdTime=Sat Sep 25 19:37:49 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1246292, encodeId=8c94124629276, content=老年性痴呆,未来还是希望借助神经电生理吧,也许更为有效!, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=neuro.Dr, createdTime=Sat Sep 25 15:59:39 CST 2021, time=2021-09-25, status=1, ipAttribution=)]
    2021-09-25 neuro.Dr

    老年性痴呆,未来还是希望借助神经电生理吧,也许更为有效!

    0

相关资讯

Blood:Kunitz抑制的非经典机制!

Ixolaris是一种强效的蜱唾液抗凝剂,可与凝血因子Xa (FXa)和酶原FX结合,形成第四纪组织因子(TF)/FVIIa/ FX(a)/Ixolaris抑制复合物。Ixolaris可阻断TF诱导的凝血和PAR2信号,预防血栓形成、肿瘤生长和免疫激活。Viviane S. De Paula等人解析了Ixolaris的高分辨率结构和动力学,并揭示了识别FX的结构基础。Ixolaris是由两个Kun

2019年国际血栓和止血学会:强生宣布抗凝剂Xarelto在儿科静脉血栓栓塞III期临床取得成功

在澳大利亚墨尔本举行的第27届国际血栓和止血学会(ISTH)上,强生的Janssen分公司宣布,Xarelto(利伐沙班)在静脉血栓栓塞(VTE)的儿科试验中取得了成功。与临床试验中的现有标准抗凝治疗相比,Xarelto治疗后复发性VTE或血栓的风险相似,且出血率相似。

FDA批准Fragmin(达肝素钠)作为儿童的第一个抗凝剂

美国食品和药物管理局已批准辉瑞公司的Fragmin(达肝素钠)注射液,以减少1个月及以上症状性静脉血栓栓塞(VTE)复发的儿科患者。

英国NICE批准拜耳的抗凝剂Xarelto用于预防动脉粥样硬化血栓

英国国家卫生与医疗保健研究院(NICE)已发布对Xarelto(利伐沙班)的最终评估决定(FAD),批准其用于预防具有缺血事件高风险的成年冠状动脉(CAD)或外周动脉疾病(PAD)患者的动脉粥样硬化血栓。以2.5 mg的剂量每日给药两次(BID)联合阿司匹林(75-100毫克)每天一次。

Stroke:替奈普酶静脉溶栓前逆转达比加群的抗凝作用

达比加群是预防心房颤动血栓的一种有效且常用的处方药。与维生素K拮抗剂不同,它不需要抗凝监测,而且抗凝作用起效快。

Stroke:服用抗凝剂的急性缺血性卒中伴房颤患者微出血和结局分析

服用OAC的房颤伴急性卒中患者,未来MACCE的风险随着CMB负担的增加而增加,而CMB的解剖位置并不影响MACCE的风险。服用华法林的患者这种风险似乎更为明显。